Mymetics announces publication in npj –Vaccines: “Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models

Epalinges, Switzerland, 3 February 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today that results from a study at the Swiss Tropical and Public Health Institute (Swiss TPH) were published on January 31, 2020 in the Nature Partner Journal (npj) Vaccines.

Media Name Media Type Description Download
Press Release pdf PDF Download